Suggested Remit: To appraise the clinical and cost effectiveness of axicabtagene ciloleucel within its marketing authorisation for treating relapsed or refractory diffuse large B-cell lymphoma.
Status In progress
Process STA 2018
ID number 1684

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
28 May 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy ID1684. We have recently invited stakeholders to respond to a written consultation on the draft scope. On receiving updated regulatory timing information from the company that is developing axicabtagene ciloleucel, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently, the consultation on the draft scope will be closed. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on
24 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance